[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-382739-105":59,"doc-detail-382739-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cd155-and-its-receptors-as-targets-for-cancer-therapy-review","CD155 and Its Receptors as Targets for Cancer Therapy - Review","","CD155, also known as the poliovirus receptor, is an adhesion molecule frequently overexpressed in diverse tumors, where it supports cell migration and proliferation. Beyond its pro-tumorigenic effects, CD155 modulates immunity during tumor progression by functioning as a ligand for the activating receptor DNAM-1 and the inhibitory checkpoint receptor TIGIT on cytotoxic lymphocytes. DNAM-1 promotes anti-tumor immune surveillance, whereas TIGIT increases in advanced stages and counterbalances DNAM-1–mediated clearance. Pre-clinical strategies target CD155 directly or enhance DNAM-1 activity, while anti-TIGIT blocking antibodies are already in clinical trials; this review summarizes these approaches and addresses the debated role of CD155.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cd155-and-its-receptors-as-targets-for-cancer-therapy-review/382739/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cd155-and-its-receptors-as-targets-for-cancer-therapy-review/382739.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-25","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is CD155 and why is it relevant to cancer therapy?","Question",{"text":112,"@type":113},"CD155 is an adhesion molecule (also called the poliovirus receptor) that is often overexpressed in tumors and can promote cell migration and proliferation. It is also a key immunomodulatory ligand affecting anti-tumor immune responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CD155 influence tumor immunity through DNAM-1 and TIGIT?",{"text":117,"@type":113},"CD155 interacts with DNAM-1 on cytotoxic immune cells, supporting tumor recognition and elimination. In advanced tumor stages, CD155 also binds inhibitory receptors such as TIGIT, which can act as an immune checkpoint and counterbalance DNAM-1–mediated clearance.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic strategies are discussed for targeting CD155-related pathways?",{"text":121,"@type":113},"The review summarizes approaches that directly target CD155 on tumor cells and strategies aimed at enhancing DNAM-1–mediated anti-tumor functions. It also covers immunotherapeutic use of anti-TIGIT blocking antibodies, including their combination in clinical trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},382739,1790318983,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review  \nCD155 and Its Receptors as Targets for Cancer Therapy  \nRossella Paolini  and Rosa Molfetta *  \nCitation: Paolini, R.; Molfetta, R. CD155 and Its Receptors as Targets for Cancer Therapy. Int. J. Mol. Sci.  \n2023, 24, 12958. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms241612958](10.3390/ijms241612958)  \nAcademic Editor: Akiyoshi Takami  \nReceived: 11 July 2023  \nRevised: 11 August 2023  \nAccepted: 17 August 2023  \nPublished: 19 August 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Molecular Medicine, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, 00161 Rome, Italy; [rossella.paolini@uniroma1.it](rossella.paolini@uniroma1.it)  \n* Correspondence: [rosa.molfetta@uniroma1.it](rosa.molfetta@uniroma1.it)  \nAbstract: CD155, also known as the poliovirus receptor, is an adhesion molecule often overexpressed in tumors of different origins where it promotes cell migration and proliferation. In addition to this pro-tumorigenic function, CD155 plays an immunomodulatory role during tumor progression since it is a ligand for both the activating receptor DNAM-1 and the inhibitory receptor TIGIT, expressed on cytotoxic innate and adaptative lymphocytes. DNAM-1 is a well-recognized receptor involved in anti-tumor immune surveillance. However, in advanced tumor stages, TIGIT is upregulated and acts as an immune checkpoint receptor, counterbalancing DNAM-1-mediated cancer cell clearance. Pre-clinical studies have proposed the direct targeting of CD155 on tumor cells as well as the enhancement of DNAM-1-mediated anti-tumor functions as promising therapeutic approaches. Moreover, immunotherapeutic use of anti-TIGIT blocking antibody alone or in combined therapy has already been included in clinical trials. The aim of this review is to summarize all these potential therapies, highlighting the still controversial role of CD155 during tumor progression.  \nKeywords: tumor immune surveillance; poliovirus receptor; cancer therapy  \n1. Introduction  \nCD155/Necl5 is a type I transmembrane glycoprotein that belongs to the Nectinsand Nectin-like (Necls) family of proteins, and it is also known as poliovirus receptor (PVR) since it allows poliovirus entry [1] . As with other members of this family, CD155 mediates important cellular processes, playing a critical role in adhesion, contact inhibition, migration, and proliferation [2,3] .  \nAlthough CD155 is constitutively expressed at a low level in different tissues including vascular endothelial cells, spinal cord motor neurons, dendritic cells (DC), and macrophages [4–6], its overexpression correlates with poor prognosis in human malignancies of different origins such as non-small cell lung cancer (NSCLC), pancreatic cancer, sarcoma, melanoma, breast cancer, colorectal cancer, and multiple myeloma (MM) [7–15] . These observations suggest that CD155 expression may confer to tumor cell more aggressive features. When expressed on tumor cells, CD155 can trigger proliferative signals and favor tumor cell migration and metastasis [3,16,17] .  \nCD155 also plays and immunoregulatory function. Indeed, it interacts with the activating receptor DNAX-associated molecule-1 (DNAM-1) expressed on the surface of cytotoxic T cells and natural killer (NK) cells, thus favoring tumor cell recognition and elimination by innate and adaptive immune responses [2,18] . On the other hand, CD155 also binds checkpoint inhibitory receptors, including T cell immunoreceptor with Ig and ITIM domains (TIGIT) and T cell-activated increased late expression (Tactile or CD96), thus counteracting DNAM-1 action in the late phas","cbCaieY61NxCe6Kv","https://ap.wps.com/l/cbCaieY61NxCe6Kv","pdf",1266982,16,"English","# Abstract\n# Introduction\n## CD155 structure and expression\n## Association with cancer prognosis\n## Immunoregulatory interactions: DNAM-1 and TIGIT\n# The Complex Role of CD155 in Tumor Progression\n## CD155 regulation during malignant transformation\n## Pro-tumorigenic versus anti-tumorigenic functions","[{\"question\":\"What is CD155 and why is it relevant to cancer therapy?\",\"answer\":\"CD155 is an adhesion molecule (also called the poliovirus receptor) that is often overexpressed in tumors and can promote cell migration and proliferation. It is also a key immunomodulatory ligand affecting anti-tumor immune responses.\"},{\"question\":\"How does CD155 influence tumor immunity through DNAM-1 and TIGIT?\",\"answer\":\"CD155 interacts with DNAM-1 on cytotoxic immune cells, supporting tumor recognition and elimination. In advanced tumor stages, CD155 also binds inhibitory receptors such as TIGIT, which can act as an immune checkpoint and counterbalance DNAM-1–mediated clearance.\"},{\"question\":\"What therapeutic strategies are discussed for targeting CD155-related pathways?\",\"answer\":\"The review summarizes approaches that directly target CD155 on tumor cells and strategies aimed at enhancing DNAM-1–mediated anti-tumor functions. It also covers immunotherapeutic use of anti-TIGIT blocking antibodies, including their combination in clinical trials.\"}]","CD155 and Its Receptors as Targets for Cancer Therapy - Review | PDF",1790252134]